Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank0
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-169.25M
↓ 118% vs avg
Percentile
P0
Near historical low
Streak
4 yr
Consecutive declineContracting
Average
$-77.75M
Historical baseline
PeriodValueYoY Change
TTM$-169.25M-7.5%
2024$-157.41M-57.6%
2023$-99.91M-24.7%
2022$-80.14M-49.2%
2021$-53.72M+29.1%
2020$-75.78M-15.3%
2019$-65.69M-104.1%
2018$-32.19M-30.8%
2017$-24.61M-30.7%
2016$-18.84M-